Purdue Pharma LP agreed to plead guilty to criminal charges over the handling of its addictive prescription opioid OxyContin, ...

Two members of the wealthy Sackler family who own OxyContin maker Purdue Pharma LP offered apologies on Thursday for the role the prescription painkiller has played in the deadly U.S. opioid epidemic ...

Indian drugmakers are expected to post steady earnings growth for the quarter ended 30 September, gaining from continued traction across global markets, although domestic sales may have been hurt by ...

The Supreme Court on Thursday rejected a nationwide settlement with OxyContin maker Purdue Pharma that would have shielded members of the Sackler family who own the company from civil lawsuits over ...

(Bloomberg) -- Creditors of Purdue Pharma voted in favor of the opioid maker’s proposal to exit bankruptcy and pay billions to communities and individuals who say they were harmed by the company’s ...

(Reuters) -Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered discounts following President Donald Trump's calls to bring down drug prices and ...

Roche Holding AG reported a 7% increase in group sales year-to-date during its Q3 2025 earnings call. Pharmaceutical sales rose by 9%, while diagnostics saw a modest 1% increase. Trading at $85.51, ...

Please send your responses to [email protected] using the email subject “SCOTUStoday feedback.” Thanks for reading! We really appreciate you being part of the SCOTUSblog community. Under ...

Year-to-date total sales growth of 12.1% at CER 1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of ...

[indiscernible] webinar 2025. My name is Henrik, and I'm the technical operator for today's call. Kindly note that the webinar is being recorded. [Operator Instructions] One last remark, if you would ...

With sales of potential blockbuster Lokelma scaling up, AstraZeneca is bolstering its production of the hyperkalemia treatment with a $445 million injection of funds. The investment will increase the ...

Following a slight delay earlier this year—and a world-first green light in the U.K. over the summer—Bayer has clinched an FDA nod to bolster the limited arsenal of nonhormonal treatments for some of ...